株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

先進ドラッグデリバリーシステムの世界市場と技術−技術に焦点を絞り込んだ分析

Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Technology

発行 BCC Research 商品コード 292626
出版日 ページ情報 英文 155 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: BCC Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
先進ドラッグデリバリーシステムの世界市場と技術−技術に焦点を絞り込んだ分析 Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Technology
出版日: 2014年01月02日 ページ情報: 英文 155 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

ドラッグデリバリーシステムは、人体内部における医薬品の移動を改善し、期待される治療効果を安全に発揮できるようにするための機能であり、製薬業界が成長を続けるうえで極めて重要な分野の1つとなっています。競争の激化、特許の期限切れ、新技術の登場といった状況に直面している製薬メーカーは、近年この分野での研究開発支出を増やす傾向にあり、新たな進歩や新製品の投入などによって、市場の成長がさらに加速する可能性もあります。先進的なドラッグデリバリーシステムの市場規模は、2013年の時点で1,819億ドルとなっており、今後年平均3.2%のペースで成長を続けることにより、2018年には2,128億ドルに達すると予想されます。

当レポートは、技術に焦点を絞り込みつつドラッグデリバリーシステムの世界市場を概観し、今後の見通しを明らかにしたもので、市場のトレンド、課題、技術革新、将来のニーズ、規制環境、関連技術などについての分析に加え、主要企業各社のプロファイルも盛り込み、概略以下の構成でお届けします。

第1章 イントロダクション

第2章 サマリー

第3章 市場の概要

  • 各種投薬形態の必要性
  • ドラッグデリバリーの技術に基づく分類
    • 持続放出ドラッグデリバリー
    • プロドラッグ
    • インプラントと子宮内避妊器具(IUD)
    • 標的化ドラッグデリバリー
    • 高分子ドラッグデリバリー
  • ドラッグデリバリーシステムの投薬経路に基づく分類
    • 経口
    • 注射および非経口
    • 口腔粘膜
    • 直腸
    • 経皮
  • 第4章 規制の諸側面
  • 2009年から2013年までの間に承認された新製品
  • FDAの製品回収と安全性に関する警告

第5章 新たな動き

  • 新たな提携、合併、買収
  • パイプライン製品

第6章 世界市場

  • 各種製品の市場
  • 各地域の市場
  • 各種最終用途向け製品の市場

第7章 先進的なドラッグデリバリーシステム市場の分析

  • 各種技術別のシステム
  • タイプ別市場
  • 地域別市場
  • 業界の構造

第8章 特許分析

  • 2009年1月から2013年7月までに承認された特許
  • カテゴリー別の特許
  • タイプ別の特許
  • 各社の特許
  • 国別の特許
  • 譲受人別の特許

第9章 現在の状況

第10章 主要企業のプロファイル

  • 3M COMPANY
  • ABBOTT LABORATORIES
  • ACTAVIS INC.
  • AKELA PHARMA INC.
  • AKORN, INC.
  • ALCON INC.
  • ALEXION PHARMACEUTICALS, INC.
  • ALKERMES
  • ALLERGAN INC.
  • AMGEN INC.
  • A.P. PHARMA
  • APTALIS PHARMA INC.
  • アステラス製薬
  • ASTRAZENECA PLC
  • ATON PHARMA
  • BAUSCH & LOMB
  • BAXTER INTERNATIONAL INC.
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOGEN IDEC
  • BIOSANTE PHARMACEUTICALS, INC.
  • BOEHRINGER INGELHEIM
  • BOSTON SCIENTIFIC
  • BRISTOL MYERS SQUIBB
  • CELGENE CORPORATION
  • CEPHALON, INC.
  • COLUMBIA LABORATORIES, INC.
  • エーザイ
  • ELAN DRUG TECHNOLOGIES
  • ENZON PHARMACEUTICALS
  • GENENTECH INC.
  • GENEREX BIOTECHNOLOGY CORPORATION
  • GENZYME CORPORATION
  • GILEAD SCIENCES, INC.
  • GLAXOSMITHKLINE PLC
  • 久光製薬
  • IMCLONE SYSTEMS INC.
  • JANSSEN BIOTECH, INC.
  • JOHNSON & JOHNSON
  • KEMPHARM, INC.
  • K.V. PHARMACEUTICAL CO.
  • LAVIPHARM CORPORATION
  • MANNKIND CORPORATION
  • MERCK & CO.
  • MYLAN LABORATORIES INC.
  • NEKTAR THERAPEUTICS
  • NEUROGESX INC.
  • NEWGEN BIOPHARMA
  • NOVARTIS AG
  • NOVAVAX, INC.
  • NOVEN PHARMACEUTICALS, INC.
  • NYCOMED US INC.
  • OSI PHARMACEUTICALS, INC.
  • PAR PHARMACEUTICAL COMPANIES, INC.
  • PDL BIOPHARMA, INC.
  • PFIZER INC.
  • QLT INC.
  • ROCHE HOLDING AG
  • SANOFI SA
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • THERAJECT, INC.
  • UMEWORLD LTD.
  • VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
  • XEL PHARMACEUTICALS, INC.

第11章 付録I

図表リスト

目次
Product Code: PHM164A

The global revenue for advanced drug delivery systems is estimated to be $181.9 billion in 2013. In 2018, revenues are estimated to reach $212.8 billion, demonstrating a compound annual growth rate (CAGR) of 3.2%.

This report provides:

  • An overview of the global market for drug delivery systems, with a focus on technology
  • Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Discussion of the current state, setbacks, innovations, and the future needs of the market.
  • Analyses of the regulatory environment and the technology involved, including the latest developments.

STUDY OBJECTIVES

A drug delivery system is one of the very important aspects in today's growth in the pharmaceutical industry. BCC Research's goal in steering this study is to provide an overview of the current and future characteristics of the market for these drug delivery systems. The key objective is to present a comprehensive analysis and future direction of these drug delivery systems as an important tool in improving the efficacy and safety of the release of drugs in the body.

This report explores the present and future strategies within the drug delivery market, which includes sustained release drug delivery, prodrug, implants and intrauterine devices (IUDs), targeted drug delivery, polymeric drug delivery, transdermal drug delivery, and transmucosal drug delivery systems. The improvisation of the market and the setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of drug delivery systems are also portrayed in this report.

A detailed analysis of drug delivery industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2013 through 2018.

Applications for drug delivery systems are also discussed in the report, with emphasis on the usage of these systems in various therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of various drug delivery systems has revealed their specific functionality in improving the transportation of a pharmaceutical compound in the body as desired to safely achieve its anticipated therapeutic effect. Modern industries have now begun to explore the advantages of these drug delivery systems in their productions and processes. This has led to the steady market for those drug delivery systems.

R&D spending, along with increasing competition, patent expiries and new technologies, are directing this in a new direction. The new advancements and new product launches have influenced the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years' of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ABOUT THE AUTHOR
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY REGION, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY REGION, 2011-2018 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • NEED FOR THE DOSAGE FORMS
    • TABLE 1: HISTORIC EVENTS IN DRUG DELIVERY
  • CLASSIFICATION OF DRUG DELIVERY ACCORDING TO TECHNOLOGY
    • SUSTAINED RELEASE DRUG DELIVERY
      • Oral Sustained Release Drug Delivery
      • Intramuscular (IM) Injections or Microsyringes
        • TABLE 2: ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG DELIVERY
    • PRODRUGS
      • Subtypes of Prodrugs
        • TABLE 3: CLASSIFICATION OF PRODRUGS
      • Need for Prodrugs
        • TABLE 4: ADVANTAGES AND DISADVANTAGES OF PRODRUGS
  • IMPLANTS AND INTRAUTERINE DEVICES (IUDS)
    • Copper-based Devices
    • Hormonal-based Devices
    • Mechanism
      • TABLE 5: ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS
  • TARGETED DRUG DELIVERY
    • Delivery Vehicles
    • Liposomes
      • TABLE 6: ADVANTAGES AND DISADVANTAGES OF LIPOSOMES
    • Micelles and Dendrimers
    • Mechanisms of Drug Delivery
    • Advantages of Dendrimers
    • Biodegradable Particles
    • Artificial DNA Nanostructures
    • Monoclonal Antibodies
    • Applications
      • TABLE 7: ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES
  • POLYMERIC DRUG DELIVERY
    • Applications of Polymers in Drug Delivery
      • TABLE 8: ADVANTAGES AND DISADVANTAGES OF POLYMERS
    • Pegylation
      • TABLE 9: ADVANTAGES AND DISADVANTAGES OF PEGYLATION
    • Future Perspectives
  • CLASSIFICATION OF DRUG DELIVERY BY ROUTE OF ADMINISTRATION
    • ORAL DRUG DELIVERY
      • TABLE 10: ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY
    • INJECTABLE OR PARENTERAL DRUG DELIVERY
      • TABLE 11: ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY
    • PULMONARY DRUG DELIVERY
      • TABLE 12: ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY
    • NASAL DRUG DELIVERY
      • TABLE 13: ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY
    • ORAL MUCOSAL DRUG DELIVERY
      • TABLE 14: ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG DELIVERY
    • RECTAL DRUG DELIVERY
      • TABLE 15: ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY
    • OCULAR DRUG DELIVERY
      • TABLE 16: ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY
    • TRANSDERMAL DRUG DELIVERY
      • TABLE 17: ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY

CHAPTER 4 - REGULATORY ASPECTS

  • NEW PRODUCTS APPROVED IN 2009-2013
    • TABLE 18: FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013
  • FDA RECALLS AND SAFETY ALERTS
    • TABLE 19: PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013
    • TABLE 20: SAFETY ALERTS, 2009 TO JUNE 2013

CHAPTER 5 - NEW DEVELOPMENTS

  • NEW PARTNERSHIPS, MERGERS AND ACQUISITION
    • TABLE 21: NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013
  • NEW PRODUCTS
    • TABLE 22: NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013
  • PIPELINE PRODUCTS
    • TABLE 23: PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET

CHAPTER 6 - GLOBAL MARKETS

  • MARKET BY TYPE
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 24: GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018 ($ MILLIONS)
      • FIGURE 1: GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 25: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)
      • FIGURE 2: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)
  • MARKET BY REGION
    • SUSTAINED RELEASE DRUG DELIVERY SYSTEM
      • Market Overview
      • Market Revenue
        • TABLE 26: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 3: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 27: MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, FOR 2012 (%)
        • FIGURE 4: MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, FOR 2012 (%)
  • PRODRUGS
    • Market Overview
    • Market Revenue
      • TABLE 28: GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 5: GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • Market Share
      • TABLE 29: MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%)
      • FIGURE 6: MARKET SHARE OF PRODRUGS DRUG DELIVERY BY REGION, 2012 (%)
  • IMPLANTS AND IUDS
    • Market Overview
    • Market Revenue
      • TABLE 30: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 7: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($ MILLIONS)
    • Market Share
      • TABLE 31: MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)
      • FIGURE 8: MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)
  • TRANSMUCOSAL DELIVERY SYSTEMS
    • Market Overview
    • Market Revenue
      • TABLE 32: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 9: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • Market Share
      • TABLE 33: MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)
      • FIGURE 10: MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)
  • TARGETED DRUG DELIVERY
    • Market Overview
    • Market Revenue
      • TABLE 34: GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 11: GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • Market Share
      • TABLE 35: MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)
      • FIGURE 12: MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)
  • TRANSDERMAL DRUG DELIVERY SYSTEM
    • Market Overview
    • Market Revenue
      • TABLE 36: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 13: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • Market Share
      • TABLE 37: MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION, 2012 ($ MILLIONS)
      • FIGURE 14: MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
  • POLYMERIC DRUG DELIVERY
    • Market Overview
    • Market Revenue
      • TABLE 38: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 15: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • Market Share
      • TABLE 39: MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)
      • FIGURE 16: MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)
  • MARKET BY END USERS
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 40: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 17: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 41: MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)
      • FIGURE 18: MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)

CHAPTER 7 - MARKET ANALYSIS FOR ADVANCED DRUG DELIVERY SYSTEMS BY TECHNOLOGY

  • TABLE 42: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY TECHNOLOGY, THROUGH 2018 ($ MILLIONS)
  • FIGURE 19: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY TECHNOLOGY, 2011-2018 ($ MILLIONS)
  • MARKET BY TYPE
    • SUSTAINED RELEASE
      • Market Overview
      • Market Revenue
        • TABLE 43: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018 ($ MILLIONS)
        • FIGURE 20: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 ($ MILLIONS)
    • PRODRUGS
      • Market Overview
      • Market Revenue
        • TABLE 44: GLOBAL REVENUE OF PRODRUGS, THROUGH 2018 ($ MILLIONS)
        • TABLE 21: NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013
    • IMPLANTS AND IUDS
      • Market Overview
      • Market Revenue
        • TABLE 45: GLOBAL REVENUE OF IMPLANTS AND IUDS*, THROUGH 2018 ($ MILLIONS)
        • FIGURE 22: GLOBAL REVENUE OF IMPLANTS AND IUDS*, 2011-2018 ($ MILLIONS)
    • TARGETED DRUG DELIVERY
      • Market Overview
        • Liposomes
        • Nanoparticles
        • Monoclonal Antibodies
      • Market Revenue
        • TABLE 46: GLOBAL REVENUE OF TARGETED DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
        • FIGURE 23: GLOBAL REVENUE OF TARGETED DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
    • POLYMERIC DRUG DELIVERY
      • Market Overview
      • Market Revenue
        • TABLE 47: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
        • FIGURE 24: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
  • MARKET BY REGION
    • MARKET OVERVIEW
    • MARKET REVENUES
      • Oral Sustained Release Delivery
        • TABLE 48: GLOBAL REVENUE OF ORAL SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 25: GLOBAL REVENUE OF ORAL SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Injectable Sustained Release Delivery
        • TABLE 49: GLOBAL REVENUE OF INJECTABLE SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 26: GLOBAL REVENUE OF INJECTABLE SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Topical Sustained Release Delivery 100
        • TABLE 50: GLOBAL REVENUE OF TOPICAL SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 27: GLOBAL REVENUE OF TOPICAL SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Prodrugs
        • TABLE 51: GLOBAL REVENUE OF PRODRUGS BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 28: GLOBAL REVENUE OF PRODRUGS BY REGION, 2011-2018 ($ MILLIONS)
      • Implants and IUDs
        • TABLE 52: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 29: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($ MILLIONS)
      • Targeted Drug Delivery
        • TABLE 53: GLOBAL REVENUE OF LIPOSOMES DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 30: GLOBAL REVENUE OF LIPOSOMES DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
        • TABLE 54: GLOBAL REVENUE OF NANOPARTICLES DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 31: GLOBAL REVENUE OF NANOPARTICLES DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
        • TABLE 55: GLOBAL REVENUE OF MONOCLONAL ANTIBODIES DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 32: GLOBAL REVENUE OF MONOCLONAL ANTIBODIES DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Polymeric Drug Delivery
        • Polymers
        • TABLE 56: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 33: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Pegylated Drugs
        • TABLE 57: GLOBAL REVENUE OF PEGYLATED DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 34: GLOBAL REVENUE OF PEGYLATED DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • INDUSTRY STRUCTURE
    • SUSTAINED RELEASE
      • Market Leaders
        • TABLE 58: MAJOR MANUFACTURERS IN SUSTAINED RELEASE DRUG DELIVERY, 2012
      • Market Share
        • TABLE 59: MARKET SHARE OF THE MANUFACTURERS IN SUSTAINED DRUG DELIVERY, 2012 (%)
        • FIGURE 35: MARKET SHARE OF THE MANUFACTURERS IN SUSTAINED DRUG DELIVERY, 2012 (%)
    • PRODRUGS
      • Market Leaders
        • TABLE 60: MAJOR MANUFACTURERS OF PRODRUGS, 2012
      • Market Share
        • TABLE 61: MARKET SHARE OF THE MANUFACTURERS IN PRODRUGS, 2012 (%)
        • FIGURE 36: MARKET SHARE OF THE MANUFACTURERS IN PRODRUGS, 2012 (%)
    • IMPLANTS AND IUDS
      • Market Leaders
        • TABLE 62: MAJOR MANUFACTURERS OF IMPLANTS AND IUDS, 2012
      • Market Share
        • TABLE 63: MARKET SHARE OF THE MANUFACTURERS OF IMPLANTS AND IUDS, 2012 (%)
        • FIGURE 37: MARKET SHARE OF THE MANUFACTURERS OF IMPLANTS AND IUDS, 2012 (%)
    • TARGETED DELIVERY
      • Market Leaders
        • TABLE 64: MAJOR MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012
      • Market Share
        • TABLE 65: MARKET SHARE OF THE MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012 (%)
        • FIGURE 38: MARKET SHARE OF THE MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012 (%)
    • POLYMERIC DRUG DELIVERY
      • Market Leaders
        • TABLE 66: MAJOR MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012
      • Market Share
        • TABLE 67: MARKET SHARE OF THE MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012 (%)
        • FIGURE 39: MARKET SHARE OF THE MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012 (%)

CHAPTER 8 - PATENT ANALYSIS

  • PATENTS BY YEAR
    • TABLE 68: NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013
    • FIGURE 40: NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013
  • PATENTS BY CATEGORY
    • TABLE 69: NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013
    • FIGURE 41: NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013
  • PATENTS BY TYPE
    • TABLE 70: NUMBER OF U.S. PATENTS BY TYPE, JANUARY 2009-JULY 2013
  • PATENTS BY COMPANY
    • TABLE 71: NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009-JULY 2013
  • PATENTS BY COUNTRY
    • TABLE 72: NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009-JULY 2013
  • PATENTS BY ASSIGNEE
    • TABLE 73: NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013
    • FIGURE 42: NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013

CHAPTER 9 - CURRENT SITUATION

CHAPTER 10 - COMPANY PROFILES

  • 3M COMPANY
  • ABBOTT LABORATORIES
  • ACTAVIS INC.
  • AKELA PHARMA INC.
  • AKORN, INC.
  • ALCON INC.
  • ALEXION PHARMACEUTICALS, INC.
  • ALKERMES
  • ALLERGAN INC.
  • AMGEN INC.
  • A.P. PHARMA
  • APTALIS PHARMA INC.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA PLC
  • ATON PHARMA
  • BAUSCH & LOMB
  • BAXTER INTERNATIONAL INC.
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOGEN IDEC
  • BIOSANTE PHARMACEUTICALS, INC.
  • BOEHRINGER INGELHEIM
  • BOSTON SCIENTIFIC
  • BRISTOL MYERS SQUIBB
  • CELGENE CORPORATION
  • CEPHALON, INC.
  • COLUMBIA LABORATORIES, INC.
  • EISAI CO., LTD
  • ELAN DRUG TECHNOLOGIES
  • ENZON PHARMACEUTICALS
  • GENENTECH INC.
  • GENEREX BIOTECHNOLOGY CORPORATION
  • GENZYME CORPORATION
  • GILEAD SCIENCES, INC.
  • GLAXOSMITHKLINE PLC
  • HISAMITSU PHARMACEUTICAL CO., INC.
  • IMCLONE SYSTEMS INC.
  • JANSSEN BIOTECH, INC.
  • JOHNSON & JOHNSON
  • KEMPHARM, INC.
  • K.V. PHARMACEUTICAL CO.
  • LAVIPHARM CORPORATION
  • MANNKIND CORPORATION
  • MERCK & CO.
  • MYLAN LABORATORIES INC.
  • NEKTAR THERAPEUTICS
  • NEUROGESX INC.
  • NEWGEN BIOPHARMA
  • NOVARTIS AG
  • NOVAVAX, INC.
  • NOVEN PHARMACEUTICALS, INC.
  • NYCOMED US INC.
  • OSI PHARMACEUTICALS, INC.
  • PAR PHARMACEUTICAL COMPANIES, INC.
  • PDL BIOPHARMA, INC.
  • PFIZER INC.
  • QLT INC.
  • ROCHE HOLDING AG
  • SANOFI SA
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • THERAJECT, INC.
  • UMEWORLD LTD.
  • VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
  • XEL PHARMACEUTICALS, INC.

CHAPTER 11 - APPENDIX I

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 1: HISTORIC EVENTS IN DRUG DELIVERY
  • TABLE 2: ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG DELIVERY
  • TABLE 3: CLASSIFICATION OF PRODRUGS
  • TABLE 4: ADVANTAGES AND DISADVANTAGES OF PRODRUGS
  • TABLE 5: ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS
  • TABLE 6: ADVANTAGES AND DISADVANTAGES OF LIPOSOMES
  • TABLE 7: ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES
  • TABLE 8: ADVANTAGES AND DISADVANTAGES OF POLYMERS
  • TABLE 9: ADVANTAGES AND DISADVANTAGES OF PEGYLATION
  • TABLE 10: ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY
  • TABLE 11: ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY
  • TABLE 12: ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY
  • TABLE 13: ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY
  • TABLE 14: ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG DELIVERY
  • TABLE 15: ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY
  • TABLE 16: ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY
  • TABLE 17: ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY
  • TABLE 18: FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013
  • TABLE 19: PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013
  • TABLE 20: SAFETY ALERTS, 2009 TO JUNE 2013
  • TABLE 21: NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013
  • TABLE 22: NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013
  • TABLE 23: PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET
  • TABLE 24: GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018 ($ MILLIONS)
  • TABLE 25: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)
  • TABLE 26: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 27: MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, FOR 2012 (%)
  • TABLE 28: GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 29: MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%)
  • TABLE 30: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 31: MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)
  • TABLE 32: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 33: MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)
  • TABLE 34: GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 35: MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)
  • TABLE 36: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 37: MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION, 2012 ($ MILLIONS)
  • TABLE 38: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 39: MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)
  • TABLE 40: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, THROUGH 2018 ($ MILLIONS)
  • TABLE 41: MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)
  • TABLE 42: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY TECHNOLOGY, THROUGH 2018 ($ MILLIONS)
  • TABLE 43: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018 ($ MILLIONS)
  • TABLE 44: GLOBAL REVENUE OF PRODRUGS, THROUGH 2018 ($ MILLIONS)
  • TABLE 21: NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013
  • TABLE 45: GLOBAL REVENUE OF IMPLANTS AND IUDS*, THROUGH 2018 ($ MILLIONS)
  • TABLE 46: GLOBAL REVENUE OF TARGETED DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
  • TABLE 47: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
  • TABLE 48: GLOBAL REVENUE OF ORAL SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 49: GLOBAL REVENUE OF INJECTABLE SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 50: GLOBAL REVENUE OF TOPICAL SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 51: GLOBAL REVENUE OF PRODRUGS BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 52: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 53: GLOBAL REVENUE OF LIPOSOMES DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 54: GLOBAL REVENUE OF NANOPARTICLES DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 55: GLOBAL REVENUE OF MONOCLONAL ANTIBODIES DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 56: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 57: GLOBAL REVENUE OF PEGYLATED DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 58: MAJOR MANUFACTURERS IN SUSTAINED RELEASE DRUG DELIVERY, 2012
  • TABLE 59: MARKET SHARE OF THE MANUFACTURERS IN SUSTAINED DRUG DELIVERY, 2012 (%)
  • TABLE 60: MAJOR MANUFACTURERS OF PRODRUGS, 2012
  • TABLE 61: MARKET SHARE OF THE MANUFACTURERS IN PRODRUGS, 2012 (%)
  • TABLE 62: MAJOR MANUFACTURERS OF IMPLANTS AND IUDS, 2012
  • TABLE 63: MARKET SHARE OF THE MANUFACTURERS OF IMPLANTS AND IUDS, 2012 (%)
  • TABLE 64: MAJOR MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012
  • TABLE 65: MARKET SHARE OF THE MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012 (%)
  • TABLE 66: MAJOR MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012
  • TABLE 67: MARKET SHARE OF THE MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012 (%)
  • TABLE 68: NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013
  • TABLE 69: NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013
  • TABLE 70: NUMBER OF U.S. PATENTS BY TYPE, JANUARY 2009-JULY 2013
  • TABLE 71: NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009-JULY 2013
  • TABLE 72: NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009-JULY 2013
  • TABLE 73: NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 1: GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 ($ MILLIONS)
  • FIGURE 2: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)
  • FIGURE 3: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 4: MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, FOR 2012 (%)
  • FIGURE 5: GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 6: MARKET SHARE OF PRODRUGS DRUG DELIVERY BY REGION, 2012 (%)
  • FIGURE 7: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 8: MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)
  • FIGURE 9: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 10: MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)
  • FIGURE 11: GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 12: MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)
  • FIGURE 13: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 14: MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
  • FIGURE 15: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 16: MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)
  • FIGURE 17: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2011-2018 ($ MILLIONS)
  • FIGURE 18: MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)
  • FIGURE 19: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY TECHNOLOGY, 2011-2018 ($ MILLIONS)
  • FIGURE 20: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 ($ MILLIONS)
  • FIGURE 22: GLOBAL REVENUE OF IMPLANTS AND IUDS*, 2011-2018 ($ MILLIONS)
  • FIGURE 23: GLOBAL REVENUE OF TARGETED DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
  • FIGURE 24: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
  • FIGURE 25: GLOBAL REVENUE OF ORAL SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 26: GLOBAL REVENUE OF INJECTABLE SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 27: GLOBAL REVENUE OF TOPICAL SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 28: GLOBAL REVENUE OF PRODRUGS BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 29: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 30: GLOBAL REVENUE OF LIPOSOMES DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 31: GLOBAL REVENUE OF NANOPARTICLES DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 32: GLOBAL REVENUE OF MONOCLONAL ANTIBODIES DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 33: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 34: GLOBAL REVENUE OF PEGYLATED DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • FIGURE 35: MARKET SHARE OF THE MANUFACTURERS IN SUSTAINED DRUG DELIVERY, 2012 (%)
  • FIGURE 36: MARKET SHARE OF THE MANUFACTURERS IN PRODRUGS, 2012 (%)
  • FIGURE 37: MARKET SHARE OF THE MANUFACTURERS OF IMPLANTS AND IUDS, 2012 (%)
  • FIGURE 38: MARKET SHARE OF THE MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012 (%)
  • FIGURE 39: MARKET SHARE OF THE MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012 (%)
  • FIGURE 40: NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013
  • FIGURE 41: NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013
  • FIGURE 42: NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013
Back to Top